Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,007,065

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Why Gilead (GILD) Might Surprise This Earnings Season

Gilead (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Why Gilead (GILD) is Poised to Beat Earnings Estimates Again

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Eylea and Dupixent Fuel Regeneron's (REGN) Q4 Earnings?

Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.

Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?

Style Box ETF report for DVY

Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $83.62, moving -0.54% from the previous trading session.

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $84.02, moving +0.95% from the previous trading session.

Gilead (GILD) to Report Q4 Earnings: What's in the Cards?

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2022 results.

GILD or GMAB: Which Is the Better Value Stock Right Now?

GILD vs. GMAB: Which Stock Is the Better Value Option?

Gilead (GILD) Gains 21% in a Year: Will the Trend Continue?

Biotech giant Gilead (GILD) gains 21% in the past 12 months as its core HIV business maintains momentum despite volatility.

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

Gilead Sciences (GILD) closed at $85.41 in the latest trading session, marking a -1% move from the prior day.

Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?

Style Box ETF report for ONEY

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?

Smart Beta ETF report for DVY

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $87.19, marking a +0.06% move from the previous day.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Is Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) a Strong ETF Right Now?

Smart Beta ETF report for LVHD

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) closed at $85.50 in the latest trading session, marking a +0.13% move from the prior day.

Gilead's (GILD) Application for Trodelvy Gets EMA Validation

Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $85.26, marking a +0.82% move from the previous day.